OncoTargets and Therapy
Volume 10, 2017 - Issue
Open access
58
Views
4
CrossRef citations to date
0
Altmetric
Original Research
Impact of prior therapies on everolimus activity: an exploratory analysis of RADIANT-4
Roberto Buzzoni1 IRCCS Foundation, National Institute of Tumors, Milan, ItalyCorrespondence[email protected]
, Carlo Carnaghi2 Humanitas Clinical and Research Center, Rozzano, Italy
, Jonathan Strosberg3 Moffitt Cancer Center, Tampa, FL, USA
, Nicola Fazio4 European Institute of Oncology, Milan, Italy
, Simron Singh5 Sunnybrook Health Sciences Centre, Toronto, ON, Canada
, Fabian Herbst6 Novartis AG, Basel, Switzerland
, Antonia Ridolfi7 Novartis Pharma S.A.S., Rueil-Malmaison, France
, Marianne E Pavel8 Medizinische Klinik 1, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany
, Edward M Wolin9 Montefiore Einstein Center for Cancer Care, Bronx, NY, USA
, Juan W Valle10 Institute of Cancer Sciences, University of Manchester, The Christie Hospital, Manchester, UK
, Do-Youn Oh11 Seoul National University Hospital, Seoul, Republic of Korea
, James C Yao12 University of Texas M.D. Anderson Cancer Center, Houston, TX, USA
& Rodney Pommier13 Oregon Health & Science University, Portland, OR, USA
show all
Pages 5013-5030
|
Published online: 16 Oct 2017
Reprints and Permissions
Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.
To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.
For more information please visit our Permissions help page.
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.